Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

Published Nov 09 2021 at 3:19 PM GMT
  • In Frequency Therapeutics" short lifetime as a company, it's had its ups and downs.
  • On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the development of a flagship hearing loss drug, and propose some directions.
  • Founded in 2015, Frequency Therapeutics has focused on a regenerative medicine.



  • Published Nov 9, 2021 3:19 PM GMT